Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.170
+0.080 (7.34%)
At close: Oct 7, 2025, 4:00 PM EDT
1.150
-0.020 (-1.71%)
After-hours: Oct 7, 2025, 5:10 PM EDT
Outlook Therapeutics Revenue
Outlook Therapeutics had revenue of $1.51M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $1.51M.
Revenue (ttm)
$1.51M
Revenue Growth
n/a
P/S Ratio
20.95
Revenue / Employee
$65,449
Employees
23
Market Cap
51.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | - | - | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
OTLK News
- 8 days ago - Outlook Therapeutics Provides Update on Type A Meeting with FDA - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics Requests Type A Meeting with FDA - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug - Invezz
- 5 weeks ago - FDA Rejects Outlook Therapeutics Eye Drug For Second Time - Benzinga
- 5 weeks ago - US FDA declines to approve Outlook Therapeutics' drug for eye condition - Reuters
- 5 weeks ago - Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision - Seeking Alpha